Review Article
Yahya Ehteshaminia; Forough Golsaz-Shirazi; Mohammad Mehdi Amiri; Fazel Shokri
Abstract
Pertussis is a highly contagious respiratory disease caused by the gram-negative bacterium Bordetella pertussis (Bp). The disease is most severe in infants and young children, whereas adolescents and adults typically experience milder symptoms but serve as important reservoirs for transmission. Despite ...
Read More
Pertussis is a highly contagious respiratory disease caused by the gram-negative bacterium Bordetella pertussis (Bp). The disease is most severe in infants and young children, whereas adolescents and adults typically experience milder symptoms but serve as important reservoirs for transmission. Despite widespread vaccination efforts, pertussis continues to pose a significant public health challenge. Historically, the first generation of pertussis vaccines, formulated as inactivated whole cell pertussis (wP) vaccines, were associated with notable side effects, prompting the development of safer acellular pertussis (aP) vaccines. The second generation of pertussis vaccines contains purified components of Bp and provides protection comparable to that of the older whole-cell vaccines. However, recent studies have reported a resurgence of pertussis, attributed to several factors, including improved diagnostic methods, waning immunity following vaccinations, and the emergence of antigenically divergent or vaccine-adapted strains. To address these challenges, researchers are developing next-generation pertussis vaccines using various approaches, such as transitioning from intramuscular to intranasal administration, formulating outer membrane vesicle (OMV)-based vaccines, designing live attenuated pertussis vaccines, and exploring nucleic acid-based vaccines and novel adjuvants aimed at inducing long-lasting mucosal and systemic immunity. This review primarily focuses on assessing the efficacy of the next-generation intranasally administered pertussis vaccines in both pre-clinical and clinical settings.
Review Article
Yuan Xia; Jing Niu; Hengheng Fan; Lin Liu; Yuan Zhou; Yuyun Xiong; Yumei Li
Abstract
Keloid, as a skin fibrotic proliferative disorder, have a complex pathogenesis that remains incompletely understood. It is characterized by abnormal and excessive scar formation following skin injury. The occurrence and development of keloids are closely associated with immune dysregulation. Immune cells, ...
Read More
Keloid, as a skin fibrotic proliferative disorder, have a complex pathogenesis that remains incompletely understood. It is characterized by abnormal and excessive scar formation following skin injury. The occurrence and development of keloids are closely associated with immune dysregulation. Immune cells, such as T cells, macrophages, mast cells, and Langerhans cells, play crucial roles in the formation of keloids. These immune cells contribute to keloid initiation and progression through mechanisms including cytokine secretion, promotion of inflammatory responses, and regulation of fibroblast proliferation and collagen synthesis. With advances in immunological research, the roles of fibroblasts, keratinocytes and melanocytes in the immunological dysregulation underlying keloids have received increasing attention. This paper aims to review recent progress on the abnormal immunological regulation involving these three epidermal cell types, in order to provide new insights and theoretical foundations for the treatment of this disease.
Letter To The Editor
Mohammad Hasan Soheilifar; Hoda Keshmiri Neghab; Sima Nobari
Abstract
Wound healing is a complex and dynamic process that encompasses four interrelated phases: hemostasis, inflammation, proliferation, and remodeling. Inflammation plays a pivotal role in both acute and chronic wound healing. In chronic diabetic wounds, the normal healing rate is impaired due to persistent ...
Read More
Wound healing is a complex and dynamic process that encompasses four interrelated phases: hemostasis, inflammation, proliferation, and remodeling. Inflammation plays a pivotal role in both acute and chronic wound healing. In chronic diabetic wounds, the normal healing rate is impaired due to persistent inflammation, which is associated with unbalanced immune responses. Microbial biofilms, increased immune cell activity, the accumulation of pro-inflammatory cytokines, and free radicals can contribute to the establishment of chronic inflammation in these wounds. Modulating the immune microenvironment in chronic wounds can significantly enhance the process of wound healing and tissue regeneration. Programmed death-ligand 1 (PD-L1) is an important immune checkpoint molecule that can bind to the PD-1 receptor on the immune cells and suppress the immunogenic responses. Although inflammation plays a significant role in wound healing, the role of PD-L1 in chronic wounds is not clearly understood. Interestingly, recent evidence indicates that fibroblast cells in granulation tissues express PD-L1. This paper will review the current findings and potential advantages of PD-L1 in the wound healing process, presenting a novel approach for treating chronic wounds.
Original Article
Eida Elmansorry
Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation and progressive destruction of joint structures. Anti-cyclic citrullinated peptide (anti-CCP) antibodies have emerged as highly specific biomarkers, whereas rheumatoid factor (RF) demonstrates ...
Read More
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation and progressive destruction of joint structures. Anti-cyclic citrullinated peptide (anti-CCP) antibodies have emerged as highly specific biomarkers, whereas rheumatoid factor (RF) demonstrates lower diagnostic specificity.
Objective: To assess the diagnostic utility of anti-CCP in comparison with rheumatoid factor (RF) in Libyan patients with RA and to investigate their associations with immunological markers, demographic characteristics, comorbid conditions , and clinical manifestations.
Methods: A cross-sectional case-control study was conducted involving70 RA patients who met the 2010 ACR/EULAR classification criteria and 70 age- and sex-matched healthy controls. Serum concentrations of anti-CCP antibodies, RF, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and complete blood count parameters were measured. Statistical analyses were performed to evaluate associations between serological markers and clinical variables, including sex, age, family history, disease activity, comorbidities, smoking status, COVID-19 vaccination, and vitamin D levels.
Results: Anti-CCP demonstrated a higher positivity rate (78.6%) compared with RF (64.3%) and was negative in all controls, whereas RF yielded false-positive results. Anti-CCP positivity was significantly associated with female sex (p = 0.026), tender joint count, CRP, ESR, neutrophil-to-lymphocyte ratio, platelet count, and mean corpuscular volume. Additional associations were identified with COVID-19 vaccination, smoking, type 1 diabetes mellitus, family history of RA, higher disease activity, and lower vitamin D levels.
Conclusion: Anti-CCP demonstrated superior diagnostic specificity and broader clinical relevance compared with RF. Its strong associations with female sex, family history of RA, comorbidities, and disease activity support the incorporation of anti-CCP testing into routine diagnostic and monitoring protocols for RA in Libya.
)
